RU2007133108A - АНТИТЕЛА, СВЯЗЫВАЮЩИЕСЯ С EphA2, И МЕТОДЫ ИХ ИСПОЛЬЗОВАНИЯ - Google Patents

АНТИТЕЛА, СВЯЗЫВАЮЩИЕСЯ С EphA2, И МЕТОДЫ ИХ ИСПОЛЬЗОВАНИЯ Download PDF

Info

Publication number
RU2007133108A
RU2007133108A RU2007133108/13A RU2007133108A RU2007133108A RU 2007133108 A RU2007133108 A RU 2007133108A RU 2007133108/13 A RU2007133108/13 A RU 2007133108/13A RU 2007133108 A RU2007133108 A RU 2007133108A RU 2007133108 A RU2007133108 A RU 2007133108A
Authority
RU
Russia
Prior art keywords
epha2
immunoglobulin
binding fragment
antigen
pta
Prior art date
Application number
RU2007133108/13A
Other languages
English (en)
Russian (ru)
Inventor
Дженни П. МЭЗЕР (US)
Дженни П. МЭЗЕР
Пенелопи Е. РОБЕРТС (US)
Пенелопи Е. РОБЕРТС
Original Assignee
Рэйвен Байотекнолоджиз, Инк. (Us)
Рэйвен Байотекнолоджиз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Рэйвен Байотекнолоджиз, Инк. (Us), Рэйвен Байотекнолоджиз, Инк. filed Critical Рэйвен Байотекнолоджиз, Инк. (Us)
Publication of RU2007133108A publication Critical patent/RU2007133108A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6817—Toxins
    • A61K47/6819—Plant toxins
    • A61K47/6825—Ribosomal inhibitory proteins, i.e. RIP-I or RIP-II, e.g. Pap, gelonin or dianthin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Nanotechnology (AREA)
  • Toxicology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
RU2007133108/13A 2005-02-04 2006-02-06 АНТИТЕЛА, СВЯЗЫВАЮЩИЕСЯ С EphA2, И МЕТОДЫ ИХ ИСПОЛЬЗОВАНИЯ RU2007133108A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65004705P 2005-02-04 2005-02-04
US60/650,047 2005-02-04

Publications (1)

Publication Number Publication Date
RU2007133108A true RU2007133108A (ru) 2009-03-10

Family

ID=36778009

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2007133108/13A RU2007133108A (ru) 2005-02-04 2006-02-06 АНТИТЕЛА, СВЯЗЫВАЮЩИЕСЯ С EphA2, И МЕТОДЫ ИХ ИСПОЛЬЗОВАНИЯ

Country Status (16)

Country Link
US (3) US7569672B2 (enExample)
EP (1) EP1846450B1 (enExample)
JP (1) JP5342145B2 (enExample)
KR (1) KR101363252B1 (enExample)
CN (2) CN104059150B (enExample)
AT (1) ATE551367T1 (enExample)
AU (1) AU2006210460B2 (enExample)
BR (1) BRPI0607450A2 (enExample)
CA (1) CA2597198C (enExample)
CR (1) CR9332A (enExample)
IL (1) IL184803A (enExample)
MX (1) MX2007009403A (enExample)
NO (1) NO20074474L (enExample)
RU (1) RU2007133108A (enExample)
WO (1) WO2006084226A2 (enExample)
ZA (1) ZA200707275B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2598711C2 (ru) * 2010-07-22 2016-09-27 Те Риджентс Оф Те Юниверсити Оф Калифорния Антитело к противоопухолевому антигену и способы применения

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7192698B1 (en) * 1999-08-17 2007-03-20 Purdue Research Foundation EphA2 as a diagnostic target for metastatic cancer
US6927203B1 (en) * 1999-08-17 2005-08-09 Purdue Research Foundation Treatment of metastatic disease
BRPI0607450A2 (pt) * 2005-02-04 2009-09-01 Raven Biotechnologies Inc anticorpos que se ligam a epha2 e métodos para sua utilização
KR20080080482A (ko) * 2005-09-07 2008-09-04 메디뮨 엘엘씨 독소가 컨쥬게이트된 ｅｐｈ 수용체 항체
ZA200900545B (en) 2006-07-18 2010-03-31 Sanofi Aventis Antagonist antibody against EPHA2 for the treatment of cancer
WO2008091908A2 (en) 2007-01-22 2008-07-31 Raven Biotechnologies Human cancer stem cells
CN101918844A (zh) * 2007-06-18 2010-12-15 米迪缪尼有限公司 表达epha2和erbb2的细胞的协同治疗
WO2009028639A1 (ja) * 2007-08-30 2009-03-05 Daiichi Sankyo Company, Limited 抗ｅｐｈａ２抗体
EP2223112A2 (en) * 2007-12-21 2010-09-01 Siemens Healthcare Diagnostics Inc. Circulating epha2 receptor
CN106349390B (zh) 2008-04-02 2019-12-10 宏观基因有限公司 Bcr-复合体-特异性抗体和其使用方法
JP5117917B2 (ja) 2008-04-21 2013-01-16 デクセリアルズ株式会社 保護素子及びその製造方法
EP2679238A1 (en) 2008-10-02 2014-01-01 Celtaxsys, INC. Methods of modulating the negative chemotaxis of immune cells
JP5734201B2 (ja) 2008-12-19 2015-06-17 マクロジェニクス，インコーポレーテッド 共有結合型ダイアボディ及びその使用
UY32914A (es) 2009-10-02 2011-04-29 Sanofi Aventis Anticuerpos que se usan específicamente al receptor epha2
US20120288481A1 (en) * 2009-11-09 2012-11-15 The Brigham And Women's Hospital, Inc. Treatment of heart disease
WO2011057249A2 (en) 2009-11-09 2011-05-12 The Brigham And Women's Hospital, Inc. Treatment of heart disease
DK2542256T3 (da) 2010-03-04 2019-08-26 Macrogenics Inc Antistoffer reagerende med b7-h3, immunologisk aktive fragmenter deraf og anvendelser deraf
PH12012501751A1 (en) 2010-03-04 2012-11-12 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
ES2667100T3 (es) 2010-08-02 2018-05-09 Macrogenics, Inc. Diacuerpos covalentes y sus usos
US9376495B2 (en) 2011-05-21 2016-06-28 Macrogenics, Inc. Deimmunized serum-binding domains and their use in extending serum half-life
WO2013033008A2 (en) 2011-08-26 2013-03-07 Merrimack Pharmaceuticals, Inc. Tandem fc bispecific antibodies
CA2850668A1 (en) * 2011-10-04 2013-04-11 Expression Pathology, Inc. Srm/mrm assay for the ephrin type-a receptor 2 protein
JP5875054B2 (ja) * 2013-02-13 2016-03-02 国立大学法人 東京大学 がんの検査方法及び検査用キット
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
SG11201506451UA (en) 2013-03-06 2015-09-29 Merrimack Pharmaceuticals Inc Anti-c-met tandem fc bispecific antibodies
US10647768B2 (en) 2014-05-29 2020-05-12 Macrogenics, Inc. Multi-chain polypeptide-containing tri-specific binding molecules
KR101636882B1 (ko) * 2015-06-25 2016-07-06 전남대학교 산학협력단 인간 피브로넥틴 도메인 Ⅲ 기본 골격의 신규 인간 ＥｐｈＡ2 특이적 결합 단백질 및 그의 용도
PE20231958A1 (es) 2015-07-30 2023-12-06 Macrogenics Inc Moleculas de union a pd-1 y metodos de uso de las mismas
CN108367069B (zh) 2015-12-14 2022-08-23 宏观基因有限公司 对于pd-1和ctla-4具有免疫反应性的双特异性分子及其使用方法
US11534466B2 (en) 2016-03-09 2022-12-27 Aal Scientifics, Inc. Pancreatic stem cells and uses thereof
CN109069633A (zh) 2016-04-15 2018-12-21 宏观基因有限公司 新颖的b7-h3-结合分子、其抗体药物缀合物及其使用方法
WO2018135653A1 (ja) * 2017-01-23 2018-07-26 学校法人東洋大学 抗ｅｐｈａ２抗体及びこれを用いたｅｐｈａ２の免疫学的検出
BR112019017628A2 (pt) 2017-02-24 2020-07-07 Macrogenics, Inc. molécula de ligação a cd137 x ta, composições farmacêuticas, uso da molécula de ligação a cd137 x ta, molécula de ligação a cd137, uso da molécula de ligação a cd137, molécula de ligação a her2/neu, uso da molécula de ligação a her2/neu, e uso de uma composição
US11795226B2 (en) 2017-12-12 2023-10-24 Macrogenics, Inc. Bispecific CD16-binding molecules and their use in the treatment of disease
CN111787949A (zh) 2018-02-15 2020-10-16 宏观基因有限公司 变体cd3-结合结构域及其在用于治疗疾病的组合疗法中的用途
JP7326764B2 (ja) * 2018-03-09 2023-08-16 東ソー株式会社 腫瘍マーカーならびに腫瘍細胞を夾雑細胞と区別して回収および検出する方法
JP7745556B2 (ja) 2020-02-21 2025-09-29 マクロジェニクス，インコーポレーテッド Ｃｄ１３７結合分子及びその使用
EP4165414A1 (en) * 2020-06-12 2023-04-19 BicycleTX Limited Treatment of diseases characterized by overexpression of erythropoietin-producing hepatocellular receptor a2 (epha2)
US20240245722A1 (en) 2021-05-25 2024-07-25 Vaxcell-Bio Monobody-based chimeric antigen receptor and immune cell including same
KR20230140746A (ko) * 2022-03-30 2023-10-10 연세대학교 산학협력단 암전이의 검출용 신규 바이오마커

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6054561A (en) 1984-02-08 2000-04-25 Chiron Corporation Antigen-binding sites of antibody molecules specific for cancer antigens
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5552391A (en) 1990-01-16 1996-09-03 La Jolla Pharmaceutical Company Chemically-defined non-polymeric valency platform molecules and conjugates thereof
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
GB9115364D0 (en) 1991-07-16 1991-08-28 Wellcome Found Antibody
CA2078539C (en) 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US5824303A (en) 1992-11-13 1998-10-20 Amgen Inc. Eck receptor ligands
US6210671B1 (en) 1992-12-01 2001-04-03 Protein Design Labs, Inc. Humanized antibodies reactive with L-selectin
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US5532159A (en) 1994-04-01 1996-07-02 The Ohio State University Monoclonal antibody to canine placental oncofetal protein for detecting cancer
US6265150B1 (en) 1995-06-07 2001-07-24 Becton Dickinson & Company Phage antibodies
ATE346865T1 (de) 1998-12-22 2006-12-15 Raven Biotechnologies Inc Zusammensetzungen und verfahren zur herstellung monoklonaler antikörper, repräsentativ für einen spezifischen zelltyp
US6927203B1 (en) 1999-08-17 2005-08-09 Purdue Research Foundation Treatment of metastatic disease
EP2289940A3 (en) 1999-08-17 2011-09-21 Purdue Research Foundation Treatment of metastatic disease
WO2001012840A2 (en) * 1999-08-17 2001-02-22 Purdue Research Foundation Anti-epha2 antibodies as a cancer diagnostic
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
US6406840B1 (en) 1999-12-17 2002-06-18 Biomosaic Systems, Inc. Cell arrays and the uses thereof
US6541225B1 (en) 2000-01-26 2003-04-01 Raven Biotechnologies, Inc. Methods and compositions for generating human monoclonal antibodies
US6441163B1 (en) 2001-05-31 2002-08-27 Immunogen, Inc. Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents
FR2838742B1 (fr) 2002-04-23 2004-07-09 Inst Nat Sante Rech Med Epitopes t de l'antigene epha2
EP1519956B1 (en) 2002-05-10 2011-09-21 Medimmune, Inc. Epha2 monoclonal antibodies and methods of use thereof
EP1575509B1 (en) 2002-05-10 2011-10-26 Purdue Research Foundation Epha2 agonistic monoclonal antibodies and methods of use thereof
BRPI0607450A2 (pt) 2005-02-04 2009-09-01 Raven Biotechnologies Inc anticorpos que se ligam a epha2 e métodos para sua utilização

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2598711C2 (ru) * 2010-07-22 2016-09-27 Те Риджентс Оф Те Юниверсити Оф Калифорния Антитело к противоопухолевому антигену и способы применения

Also Published As

Publication number Publication date
CN104059150A (zh) 2014-09-24
US20100086969A1 (en) 2010-04-08
CN104059150B (zh) 2018-10-02
JP5342145B2 (ja) 2013-11-13
WO2006084226A3 (en) 2006-11-30
KR20070107721A (ko) 2007-11-07
CN101155830B (zh) 2014-06-18
WO2006084226A2 (en) 2006-08-10
US8183357B2 (en) 2012-05-22
EP1846450A2 (en) 2007-10-24
IL184803A0 (en) 2007-12-03
NO20074474L (no) 2007-11-05
MX2007009403A (es) 2007-10-02
US7569672B2 (en) 2009-08-04
US7776328B2 (en) 2010-08-17
BRPI0607450A2 (pt) 2009-09-01
EP1846450A4 (en) 2008-05-28
KR101363252B1 (ko) 2014-02-13
CA2597198C (en) 2016-06-21
CR9332A (es) 2008-03-18
ZA200707275B (en) 2009-01-28
AU2006210460A2 (en) 2006-08-10
HK1108163A1 (en) 2008-05-02
JP2008529497A (ja) 2008-08-07
CA2597198A1 (en) 2006-08-10
ATE551367T1 (de) 2012-04-15
CN101155830A (zh) 2008-04-02
EP1846450B1 (en) 2012-03-28
AU2006210460A1 (en) 2006-08-10
US20090263391A1 (en) 2009-10-22
IL184803A (en) 2011-04-28
US20060177453A1 (en) 2006-08-10
AU2006210460B2 (en) 2012-04-05

Similar Documents

Publication Publication Date Title
ES2829206T3 (es) Moduladores novedosos y procedimientos de uso
JP2008529497A5 (enExample)
CN104334580B (zh) 抗sez6抗体及使用方法
JP6515111B2 (ja) 新規の抗クローディン抗体および使用方法
JP3213314B2 (ja) 幹細胞因子レセプターに対するモノクローナル抗体
JP2024059609A5 (enExample)
JP5631733B2 (ja) 抗ＥｐＣＡＭ抗体およびその使用
US20190022241A1 (en) Novel sez6 modulators and methods of use
US9056911B2 (en) Antibody against carcinoembryonic antigen and uses thereof
JP2021526022A5 (enExample)
JP2002515511A (ja) 放射線及び成長因子レセプター・チロシン・キナーゼのインヒビターを使用するヒト腫瘍の治療
IL184803A (en) Purified antibodies against epha2, methods for their production, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for treating cancer
JP2016509014A (ja) 新規の多特異的構成物
JP2017500028A (ja) 新規の抗ｄｐｅｐ３抗体および使用方法
RU2012137515A (ru) Антитела, связывающиеся с лизилоксидазоподобным ферментом-2 (loxl2), и способы их применения
JP2005514409A (ja) Ｍｕｃ１８抗原に対する抗体の使用
RU2014113304A (ru) Анти-cd40-антитела, применение и методы
NZ597067A (en) Monoclonal antibodies expressed by ATCC PTA-4621 for the treatment of cancer
JP2020522280A5 (enExample)
JP2020522281A5 (enExample)
JP2014515600A5 (enExample)
CN110563843A (zh) 一种靶向人vista蛋白的单克隆抗体
CN116615248A (zh) 抗体-药物缀合物和cdk9抑制剂的组合
WO2017177199A2 (en) Plectin-1 binding antibodies and uses thereof
JP2025524306A (ja) Ｉｔｇａ２を標的とする抗体及びそれを含む抗体薬物複合体

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20090313